Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | May 5, 2021 | News story | Research and Development | COVID-19, COVID-19 vaccine, covid 19 news, covid-19 news, pharma, pharma news
The past week has seen more COVID-19 vaccine and treatment news: Moderna will supply up to 500 million jabs to the COVAX worldwide vaccination programme, Celltrion’s treatment has shown promise against the South African variant of the virus, and a study has suggested that just a single dose of a vaccine may cut transmissions in half.
1. Moderna to supply up to 500 million COVID-19 vaccines to COVAX – Published 04/05/2021
Moderna have announced a supply agreement with Gavi, the Vaccine Alliance, for up to 500 million doses of their COVID-19 vaccine, including an initial 34 million doses to be delivered in the fourth quarter of 2021.
2. Celltrion’s COVID-19 treatment shows promise against South African variant – Published 30/04/21
Celltrion’s regdanvimab treatment for COVID-19 has shown itself to be effective against the South African variant of the virus, according to preliminary results from a pre-clinical trial.
3. Moderna up investments to produce 3 billion COVID vaccine doses in 2022 – Published 29/04/21
Moderna have announced it is making new funding commitments to increase supply at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its COVID-19 vaccine.
4. COVID Symptom Study app reveals most common vaccine side effects – Published – 28/04/21
An analysis of over 600,000 people’s vaccine reports has been published in The Lancet Infectious Diseases journal, in the largest real-life study of COVID-19 vaccine side-effects in the world.
5. Single dose of COVID vaccine can cut transmissions in half – Published 28/04/21
A Public Health England (PHE) study into the Pfizer-BioNTech and Oxford-AstraZeneca vaccines has found that a single dose of either jab can cut COVID-19 transmissions by up to half.
Jack Goddard
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …
